poly ADP-ribose polymerase (PARP) inhibitor for COVID-19 - living meta-analysis of clinical studies

display ongoing

results: demonstrated suggested inconclusive safety concern ongoing study

	breast cancer - adjuvant	breast cancer - triple negative

	breast cancer - adjuvant	es-BC - TNBC - NA - all population	mBC - TNBC - L1 - all population	mBC-Triple negative (TNBC) - 2nd Line (L2)	mBC - TNBC - L2 - all population
poly ADP-ribose polymerase (PARP) inhibitor
olaparib	OlympiA ...	OlympiA ...			OlympiAD
talazoparib				EMBRACA
veliparib plus paclitaxel plus carboplatin			BrighTNess ... BrighTNess ...

Study type: